Year-end Sale % OFF 
Abstract
Background: In the Reduction of Endpoints in NIDDM (noninsulin–dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan study (RENAAL study), Losartan reduced the risk of the doubling of serum creatinine concentration by 25% and of end stage renal disease ESRD) by 28%. Methods: 40 albino rats were enrolled in this study, and they were divided into four main groups, each group 10 rats. Where, group I, serves as a control, and group II was reated with Gentamicin 80mg/kg. The group III was treated with Losartan. While, group IV was treated with Losartan and Gentamicin. Results: Showed that Losartan has statistically significant nephro-protective effects. Their nephroprotective effects were assessed by:-1- histopathological studies. 2- Measuring serum levels of BUN, and, creatinnine. Conclusion: Losartan has renal-protective effects.
Highlights
Losartan 50 mg resulted in significant reductions of systolic and diastolic blood pressure at 24 hours after dosing
In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study (RENAAL study), Losartan reduced the risk of the doubling of serum creatinine concentration by 25% and of end stage renal disease (ESRD) by 28% (Brenner et al, 2001)
This level showed no significant change compared to control group (28.2±1.5mg/dl), This study found that gentamicin and Losartan treated group, thier mean serum urea levels was 60.4±1.2 mg/dl
Summary
Losartan 50 mg resulted in significant reductions of systolic and diastolic blood pressure at 24 hours after dosing. In patients with type 2 diabetes mellitus, Angiotensin II receptor blockers (ARBs) are especially effective for decreasing nephropathy progression rate, independent of their blood pressure–lowering effect. In the Reduction of Endpoints in NIDDM (noninsulin–dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan study (RENAAL study), Losartan reduced the risk of the doubling of serum creatinine concentration by 25% and of end stage renal disease (ESRD) by 28% (Brenner et al, 2001). The decreased risks of ESRD (26%) and or death (19%) remained unchanged after adjustment for blood pressure, indicating reno-protection was independent of blood pressure reduction (Brenner et al, 2001). Losartan has been found to down-regulate the expression of transforming growth factor beta (TGF-β) types I and II receptors in the kidney of diabetic rats, which may partially account for its nephro-protective effects (Guo and Qiu, 2003)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
